Deep Neural Networks Can Predict New-Onset Atrial Fibrillation From the 12-Lead ECG and Help Identify Those at Risk of Atrial Fibrillation-Related Stroke

Sushravya Raghunath, John M Pfeifer, Alvaro E Ulloa-Cerna, Arun Nemani, Tanner Carbonati, Linyuan Jing, David P vanMaanen, Dustin N Hartzel, Jeffery A Ruhl, Braxton F Lagerman, Daniel B Rocha, Nathan J Stoudt, Gargi Schneider, Kipp W Johnson, Noah Zimmerman, Joseph B Leader, H Lester Kirchner, Christoph J Griessenauer, Ashraf Hafez, Christopher W Good, Brandon K Fornwalt, Christopher M Haggerty, Sushravya Raghunath, John M Pfeifer, Alvaro E Ulloa-Cerna, Arun Nemani, Tanner Carbonati, Linyuan Jing, David P vanMaanen, Dustin N Hartzel, Jeffery A Ruhl, Braxton F Lagerman, Daniel B Rocha, Nathan J Stoudt, Gargi Schneider, Kipp W Johnson, Noah Zimmerman, Joseph B Leader, H Lester Kirchner, Christoph J Griessenauer, Ashraf Hafez, Christopher W Good, Brandon K Fornwalt, Christopher M Haggerty

Abstract

Background: Atrial fibrillation (AF) is associated with substantial morbidity, especially when it goes undetected. If new-onset AF could be predicted, targeted screening could be used to find it early. We hypothesized that a deep neural network could predict new-onset AF from the resting 12-lead ECG and that this prediction may help identify those at risk of AF-related stroke.

Methods: We used 1.6 M resting 12-lead digital ECG traces from 430 000 patients collected from 1984 to 2019. Deep neural networks were trained to predict new-onset AF (within 1 year) in patients without a history of AF. Performance was evaluated using areas under the receiver operating characteristic curve and precision-recall curve. We performed an incidence-free survival analysis for a period of 30 years following the ECG stratified by model predictions. To simulate real-world deployment, we trained a separate model using all ECGs before 2010 and evaluated model performance on a test set of ECGs from 2010 through 2014 that were linked to our stroke registry. We identified the patients at risk for AF-related stroke among those predicted to be high risk for AF by the model at different prediction thresholds.

Results: The area under the receiver operating characteristic curve and area under the precision-recall curve were 0.85 and 0.22, respectively, for predicting new-onset AF within 1 year of an ECG. The hazard ratio for the predicted high- versus low-risk groups over a 30-year span was 7.2 (95% CI, 6.9-7.6). In a simulated deployment scenario, the model predicted new-onset AF at 1 year with a sensitivity of 69% and specificity of 81%. The number needed to screen to find 1 new case of AF was 9. This model predicted patients at high risk for new-onset AF in 62% of all patients who experienced an AF-related stroke within 3 years of the index ECG.

Conclusions: Deep learning can predict new-onset AF from the 12-lead ECG in patients with no previous history of AF. This prediction may help identify patients at risk for AF-related strokes.

Keywords: atrial fibrillation; atrial flutter; deep learning; neural network; prediction; stroke.

Figures

Figure 1.
Figure 1.
Flow chart illustrating the study design and data summary.A, Data exclusions and data definition of proof-of-concept model. B, Data flow for deployment model. AF indicates atrial fibrillation.
Figure 2.
Figure 2.
Illustration of model performance for all, normal, and abnormal subpopulations. The model performance is represented for proof-of-concept model as area under the receiver operating characteristic (left) and precision-recall curves (right). The bars represent the mean performance across the 5-fold cross-validation with error bars showing 95% CIs. The black circle represents the M0 model performance on the holdout set. The 3 bars represent model performance for extreme gradient boosting (XGBoost) model with age and sex as inputs (gray); DNN model with digital ECG traces as input (DNN-ECG; orange); and DNN model with digital ECG traces, age, and sex as inputs (DNN-ECG-AS; blue). AF indicates atrial fibrillation; and ROC, receiver operating characteristic.
Figure 3.
Figure 3.
ROC curves, incidence-free KM survival curves, and HRs in subpopulations for the 3 models evaluated on the holdout set. The 3 models are XGBoost model with age and sex only (blue); DNN model with ECG traces only (DNN-ECG; red); and DNN model with ECG traces, age, and sex (DNN-ECG-AS; black) for all ECGs in the holdout set. A, ROC curves with operating points marked for the 3 models. B, Incidence-free KM curves for the high- and low-risk groups for the operating point shown in A for a follow-up of 30 years. Note that curves corresponding to the low-risk group for all 3 models overlap. C, The plot of HR with 95% CIs for the 3 models in subpopulations defined by age groups, sex, and normal or abnormal ECG label. Note that there is no HR for age <50 years for the first model as there was no subject classified as high-risk for new-onset atrial fibrillation by the model for that subpopulation. DNN indicates deep neural network; HR, hazard ratio; KM, Kaplan-Meier; and ROC, receiver operating characteristic.
Figure 4.
Figure 4.
Incidence-free KM survival curves within the holdout set for subpopulations defined by sex, and age groups. The top row shows the KM curves for subpopulations in age groups: <50 years, 50 to 65 years, and ≥65 years for men (left) and women (right). The bottom row shows the KM curves for the model-predicted (model M0 trained with ECG traces, age, and sex; DNN-ECG-AS) low-risk groups and high-risk groups for new-onset atrial fibrillation for each age group for men and women. It also reflects relative hazards between age groups. The horizontal dotted gray line represents incidence-free proportion of 50%, and vertical lines represent the median survival time for the respective curves. DNN indicates deep neural network; and KM, Kaplan-Meier.
Figure 5.
Figure 5.
Illustration of model sensitivity to detect patients at risk of AF-related strokes as a function of the proportion of the population flagged as high risk to develop new-onset AF. Colored curves denote patients with strokes occurring within 1 (blue), 2 (orange), and 3 (green) years after ECG in the deployment test set. Gray dotted lines represent the corresponding optimal operating thresholds from Table II in the Data Supplement. AF indicates atrial fibrillation.

References

    1. Britton M, Gustafsson C. Non-rheumatic atrial fibrillation as a risk factor for stroke. Stroke. 1985;16:178–181. doi: 10.1161/01.STR.16.2.182
    1. Wolf PA, Dawber TR, Thomas HE, Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973–977. doi: 10.1212/wnl.28.10.973
    1. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–364. doi: 10.1016/s0002-9343(02)01236-6
    1. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66:1714–1728. doi: 10.1016/j.jacc.2015.08.038
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867. doi: 10.7326/0003-4819-146-12-200706190-00007
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. ; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. doi: 10.1056/NEJMoa0905561
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. ; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi: 10.1056/NEJMoa1009638
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. ; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. doi: 10.1056/NEJMoa1107039
    1. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224–227. doi: 10.1161/01.cir.89.1.224
    1. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R, Pouliot E, Ziegler PD; REVEAL AF Investigators. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF Study. JAMA Cardiol. 2017;2:1120–1127. doi: 10.1001/jamacardio.2017.3180
    1. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, et al. ; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–129. doi: 10.1056/NEJMoa1105575
    1. Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, Carter C, Baca-Motes K, Felicione E, Sarich T, et al. . Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial. JAMA. 2018;320:146–155. doi: 10.1001/jama.2018.8102
    1. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, Balasubramanian V, Russo AM, Rajmane A, Cheung L, et al. ; Apple Heart Study Investigators. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909–1917. doi: 10.1056/NEJMoa1901183
    1. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, Yan L, Xing Y, Shi H, Li S, et al. ; MAFA II Investigators. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol. 2019;74:2365–2375. doi: 10.1016/j.jacc.2019.08.019
    1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953. doi: 10.1093/eurheartj/ehi825
    1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–484. doi: 10.1016/S0002-9343(99)80348-9
    1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB, Massaro JM, Beiser A, Wolf PA, et al. . Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–1046. doi: 10.1161/01.CIR.0000140263.20897.42
    1. Turakhia MP, Ziegler PD, Schmitt SK, Chang Y, Fan J, Than CT, Keung EK, Singer DE. Atrial fibrillation burden and short-term risk of stroke: case-crossover analysis of continuously recorded heart rhythm from cardiac electronic implanted devices. Circ Arrhythm Electrophysiol. 2015;8:1040–1047. doi: 10.1161/CIRCEP.114.003057
    1. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, Creager MA, Eckel RH, Elkind MS, Fornage M, et al. ; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754–3832. doi: 10.1161/STR.0000000000000046
    1. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005;9:iii–iv, ix. doi: 10.3310/hta9400
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, et al. . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210
    1. Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, Carter RE, Yao X, Rabinstein AA, Erickson BJ, et al. . An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019;394:861–867. doi: 10.1016/S0140-6736(19)31721-0
    1. Raghunath S, Ulloa Cerna AE, Jing L, vanMaanen DP, Stough J, Hartzel DN, Leader JB, Kirchner HL, Stumpe MC, Hafez A, et al. . Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network. Nat Med. 2020;26:886–891. doi: 10.1038/s41591-020-0870-z
    1. Goldberger EThe aVl, aVr, and aVf leads. A simplification of standard lead electrocardiography. Am Heart J. 1942;24:378–396. doi: 10.1016/S0002-8703(42)90821-4
    1. Chen T, Guestrin C. XGBoost: A scalable tree boosting system. 2016In: Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. New York, NY: Association for Computing Machinery; 785–794.
    1. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JD, Janssens AC, et al. . Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102. doi: 10.1161/JAHA.112.000102
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958;53:457–481. doi: 10.2307/2281868
    1. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–202. doi: 10.1111/j.2517-6161.1972.tb00899.x
    1. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35. doi: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>;2-3
    1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM, Andresen D, Camm AJ, Davies W, Capucci A, Olsson B, et al. . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263–272. doi: 10.1378/chest.09-1584
    1. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, Ambrose M, Alonso A. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107:85–91. doi: 10.1016/j.amjcard.2010.08.049
    1. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D’Agostino RB, Sr, Newton-Cheh C, Yamamoto JF, Magnani JW, Tadros TM, et al. . Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373:739–745. doi: 10.1016/S0140-6736(09)60443-8
    1. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, et al. . Stroke associated with atrial fibrillation–incidence and early outcomes in the north Dublin population stroke study. Cerebrovasc Dis. 2010;29:43–49. doi: 10.1159/000255973
    1. Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45:2599–2605. doi: 10.1161/STROKEAHA.114.006070
    1. Lin HJ, Wolf PA, Benjamin EJ, Belanger AJ, D’Agostino RB. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. Stroke. 1995;26:1527–1530. doi: 10.1161/01.str.26.9.1527
    1. Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:279–296. doi: 10.7326/M15-2886
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, et al. ; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328. doi: 10.1056/NEJMoa0810084
    1. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307–312. doi: 10.1136/bmj.317.7154.307
    1. Koltowski L, Balsam P, Glłowczynska R, Rokicki JK, Peller M, Maksym J, Blicharz L, Maciejewski K, Niedziela M, Opolski G, Grabowski M. Kardia Mobile applicability in clinical practice: a comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center [published online January 15, 2019]. Cardiol J. doi: 10.5603/cj.a2019.0001.
    1. A Study to Determine If Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke (GUARD-AF) . 2019. Accessed January 4, 2021.
    1. Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H, Kautzner J, Mont L, Morgan J, Ng A, et al. . The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. Eur Heart J. 2015;36:255–256. doi: 10.1093/eurheartj/ehu476
    1. Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-induced cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2328–2344. doi: 10.1016/j.jacc.2019.02.045
    1. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731–2738. doi: 10.1093/eurheartj/eht194
    1. Morandi A, Limousin M, Sayers J, Golwala SR, Czakon NG, Pierpaoli E, Jullo E, Richard J, Ameglio S. X-ray, lensing and Sunyaev-Zel’dovich triaxial analysis of Abell 1835 out to R 200. Mon Not R Astron Soc. 2012;425:2069–2082.
    1. Ioffe S, Szegedy C. Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift. 2015. Accessed January 4, 2021
    1. Duchi J, Hazan E, Singer Y. Adaptive subgradient methods for online learning and stochastic optimization. J Mach Learn Res. 2011;12:2121–2159.
    1. Lin M, Chen Q, Yan S. Network in network. 2014. In: 2nd International Conference on Learning Representations, ICLR 2014 - Conference Track Proceedings. Accessed January 4, 2021.
    1. Prechelt L. Early stopping-but when? In: Neural Networks: Tricks of the Trade. 1998. Springer; 55–69.

Source: PubMed

3
Předplatit